Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product ownership
Newsflash:
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product ownership
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product ownership
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully misappropriated a …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product …
Listen Now
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product ownership
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully misappropriated a targeted protein degradation trade secret
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare against an outdated, lower Ozempic dose while ignoring the higher dose the FDA approved more than four years ago
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, precision medicine, and sponsors seeking flexible capacity outside their home markets
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?